Samuel Hopkins
Plus aucun poste en cours
Historique de carrière de Samuel Hopkins
Anciens postes connus de Samuel Hopkins
Sociétés | Poste | Début | Fin |
---|---|---|---|
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Directeur Technique/Scientifique/R&D | 01/01/2001 | 01/01/2001 |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Directeur Technique/Scientifique/R&D | - | - |
SCYNEXIS, INC. | Directeur Technique/Scientifique/R&D | 23/10/2009 | - |
Formation de Samuel Hopkins
Western University of Health Sciences | Undergraduate Degree |
Medical College of Virginia | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
SCYNEXIS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Commercial Services |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
- Bourse
- Insiders
- Samuel Hopkins
- Expérience